Savara

SVRA · NASDAQ

$4.76+$0.13 (+2.81%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $4.63

Latest news

Press releaseOct 12, 4:05 PM ETBusiness Wire
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
Press releaseAug 24, 4:05 PM ETBusiness Wire
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Press releaseAug 20, 4:05 PM ETBusiness Wire
Savara Announces New Employment Inducement Grant
Press releaseAug 11, 4:05 PM ETBusiness Wire
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
Press releaseJul 30, 8:05 AM ETBusiness Wire
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
Press releaseJun 30, 7:30 AM ETGlobe Newswire
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
Press releaseJun 12, 4:05 PM ETBusiness Wire
Savara Announces New Employment Inducement Grant
Press releaseJun 8, 4:05 PM ETBusiness Wire
Savara Announces Chief Financial and Administrative Officer Transition
Press releaseMay 27, 4:05 PM ETBusiness Wire
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
Press releaseMay 20, 8:15 AM ETBusiness Wire
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
Press releaseMay 19, 2:15 PM ETBusiness Wire
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Press releaseMay 18, 2:55 PM ETBusiness Wire
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Press releaseMay 12, 4:05 PM ETBusiness Wire
Savara Reports First Quarter Financial Results and Provides Business Update
Press releaseMay 11, 4:05 PM ETBusiness Wire
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
Press releaseApr 17, 4:05 PM ETBusiness Wire
Savara Announces New Employment Inducement Grant
Press releaseApr 15, 4:05 PM ETBusiness Wire
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Press releaseApr 14, 8:05 AM ETBusiness Wire
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
NewsApr 7, 8:13 AM ET
Savara's MOLBREEVI MAA Accepted By MHRA For Autoimmune PAP, Joining Ongoing FDA And EMA Reviews With Decisions Expected Across U.S., EU, And U.K. Within 12 Months
Press releaseApr 7, 8:05 AM ETBusiness Wire
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Press releaseMar 30, 8:05 AM ETBusiness Wire
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Press releaseMar 13, 8:05 AM ETBusiness Wire
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
Press releaseMar 6, 4:05 PM ETBusiness Wire
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Press releaseMar 4, 4:05 PM ETBusiness Wire
Savara Announces Participation in 2026 Citizens Life Sciences Conference
Press releaseFeb 20, 4:15 PM ETBusiness Wire
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Press releaseFeb 13, 4:05 PM ETBusiness Wire
Savara Announces New Employment Inducement Grant
Press releaseFeb 4, 4:05 PM ETBusiness Wire
Savara Announces Participation in Upcoming Investor Healthcare Conferences
Press releaseJan 27, 8:05 AM ETBusiness Wire
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
NewsJan 27, 7:05 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsDec 23, 8:17 AM ETAvi Kapoor
Meta Platforms To $815? Here Are 10 Top Analyst Forecasts For Tuesday
NewsNov 28, 11:19 AM ETAvi Kapoor
Micron, Endeavour Silver, First Majestic Silver, Applied Digital And Other Big Stocks Moving Higher On Friday
NewsMay 27, 12:24 PM ETAvi Kapoor
Dow Surges Over 600 Points; US Durable Goods Orders Fall in April
NewsMay 27, 10:20 AM ETAvi Kapoor
Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings
NewsMar 21, 8:10 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsMar 18, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

Savara Announces New Employment Inducement Grant

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors

Savara Announces New Employment Inducement Grant

Savara Announces Chief Financial and Administrative Officer Transition

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Reports First Quarter Financial Results and Provides Business Update

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

Savara Announces New Employment Inducement Grant

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

Savara's MOLBREEVI MAA Accepted By MHRA For Autoimmune PAP, Joining Ongoing FDA And EMA Reviews With Decisions Expected Across U.S., EU, And U.K. Within 12 Months

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Announces New Employment Inducement Grant

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Meta Platforms To $815? Here Are 10 Top Analyst Forecasts For Tuesday

Micron, Endeavour Silver, First Majestic Silver, Applied Digital And Other Big Stocks Moving Higher On Friday

Dow Surges Over 600 Points; US Durable Goods Orders Fall in April

Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session